[关键词]
[摘要]
目的 探讨还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者的有效性与安全性。方法 选择2014年1月-2016年5月在郑州市第七人民医院诊治的尿毒症贫血患者84例作为研究对象,根据随机信封抽签原则分为观察组与对照组各42例,对照组给予血液透析与口服促红细胞生成素治疗,观察组在对照组治疗的基础上给予还原型谷胱甘肽治疗,两组均治疗观察12周。结果 两组治疗期间都无严重并发症发生,治疗后观察组总有效率(97.6%)明显高于对照组(85.7%),差异有统计学意义(P<0.05)。观察组与对照组治疗后的血清尿酸(UA)值明显低于治疗前,而血清内生肌酐清除率(Ccr)明显高于治疗前,组内对比都有统计学意义(P<0.05);同时治疗后观察组的血清UA明显低于对照组,Ccr值明显高于对照组,差异有统计学意义(P<0.05)。观察组治疗后的血红细胞(RBC)与血红蛋白(Hb)值分别为(3.38±0.34)×1012/L和(94.55±4.92)g/L,而对照组分别为(2.56±0.38)×1012/L和(73.24±5.39)g/L,都明显高于治疗前(P<0.05),且观察组也明显高于对照组,差异有统计学意义(P<0.05)。结论 还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者可改善肾功能与贫血状态,提高治疗疗效,安全性好,有很好的应用推广价值。
[Key word]
[Abstract]
Objective To explore the effectiveness and safety of reduced glutathione in the treatment of uremic patients with anemia. Methods From January 2014 to May 2016, 84 uremic patients with anemia in our hospital for treatment were selected as the research object and were equally divided into the observation group and control group with 42 patients in each group accorded to the random draw envelope principle. The control group was treated with hemodialysis and oral administration of erythropoietin therapy, the observation group was received the reduced glutathione treatment based on the control group, all patients were observed for 12 weeks. Results There were no serious complications in the two groups. The total effective rate of the observation group and the control group were 97.6% and 85.7% respectively. The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The serum UA values in observation group and the control group after treatment were significantly lower than that before treatment, the serum Ccr value were significantly higher than before treatment (P<0.05), At the same time after treatment, the serum UA and Ccr values in the observation group compared with the control group were statistical significance difference (P<0.05). The RBC and Hb in the observation group after treatment were (3.38 ±0.34)×1012/L and (94.55 ±4.92) g/L, and the control group were (2.56 ±0.38)×1012/L and (73.24 ±5.39) g/L respectively that were significantly higher than before treatment (P<0.05), and the observation group were significantly higher than those in control group (P<0.05). Conclusion Reduced glutathione in the treatment of uremic anemia can improve renal function and anemia status, improve the therapeutic efficacy, its better safety, and has a good value of application and promotion.
[中图分类号]
[基金项目]